Drugs / Fylntera
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06918587 Comparator | Sep 2024 → May 2025 | neutropenia | Kashiv BioSciences, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fylntera | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06918587 ↗ |
| Route | Subcutaneous | “single 6 mg dose administered through subcutaneous route” NCT06918587 ↗ |